Phase II study of aminothiadiazole in advanced squamous cell carcinoma of the esophagus.
Twenty-three patients with advanced inoperable squamous cell carcinoma of the esophagus were treated with aminothiadiazole (A-TD) 125 mg/m2 weekly plus allopurinol daily in a phase II cooperative group trial. No patients responded to treatment; 17 patients progressed, three showed stable disease, and three were unevaluable. There were no life-threatening hematologic or metabolic toxicities. The median survival from study entry was 5 months. A-TD is not active in advanced squamous cell carcinoma of the esophagus.
Engstrom
P F
PF
Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Ryan
L M
LM
Falkson
G
G
Haller
D G
DG
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000493:Allopurinol / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D004341:Drug Evaluation; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D013830:Thiadiazoles / Q000008:administration & dosage*
D000970:Antineoplastic Agents; D013830:Thiadiazoles; D000493:Allopurinol; C010852:2-amino-1,3,4-thiadiazole